Veracyte
Veracyte Q1 Revenues up 18 Percent, Driven by Core Tests
The company continues to see increased adoption of its Decipher and Afirma tests, and said it is making changes to its IVD manufacturing business.
The company welcomed favorable results last week from a study comparing its test to a narrower ddPCR-based approach in patients from an ongoing interventional trial.
Craig-Hallum Initiates Coverage of Veracyte With Buy Rating, $45 Price Target
The investment bank views the company as a promising target with a strong track record and prospects for expansion into new, under-penetrated markets.
Veracyte Eyes Dropping IVD/Pharma Subsidiary in Europe As Growth Concentrates Among Clinical LDTs
Premium
Company officials lauded its core tests and shared news about launches planned for the upcoming year, including its minimal residual disease assay.
GenomeWeb Top 40 Drops 3 Percent in 2024, Reflecting Larger Life Science Struggles in Stock Market
The Dow Jones Industrial Average rose 13 percent year over year, and the Nasdaq rose 29 percent, but the Nasdaq Biotech Index declined 1 percent.